Q3 2020 13F Holders as of 9/30/2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
28M
-
Number of holders
-
69
-
Total 13F shares, excl. options
-
17.6M
-
Shares change
-
-1.9M
-
Total reported value, excl. options
-
$155M
-
Value change
-
-$77.1M
-
Put/Call ratio
-
0.5
-
Number of buys
-
32
-
Number of sells
-
-43
-
Price
-
$8.80
Significant Holders of NextCure, Inc. - Common Stock (NXTC) as of Q3 2020
98 filings reported holding NXTC - NextCure, Inc. - Common Stock as of Q3 2020.
NextCure, Inc. - Common Stock (NXTC) has 69 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 17.6M shares
of 28M outstanding shares and own 62.66% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (2.71M shares), Sofinnova Investments, Inc. (2.67M shares), Canaan Partners X LLC (1.71M shares), BlackRock Inc. (1.23M shares), CITADEL ADVISORS LLC (1.08M shares), MORGAN STANLEY (1.07M shares), ArrowMark Colorado Holdings LLC (723K shares), HILLHOUSE CAPITAL ADVISORS, LTD. (638K shares), Voya Investment Management LLC (573K shares), and DEUTSCHE BANK AG\ (551K shares).
This table shows the top 69 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.